AGK

AGK is a mitochondrial multi-substrate lipid kinase that phosphorylates diacylglycerol, ceramide, and monoacylglycerol—but not sphingosine—to generate phosphatidic and lysophosphatidic acid, with activity modulated by cardiolipin, sphingosine, and calcium/magnesium ratios (PMID:15252046). A defining feature emerging across genetic models is that AGK exerts several of its physiological roles independently of this catalytic activity, dissected through paired knockout and kinase-dead (G126E) mouse alleles: it stabilizes mitochondrial respiratory chain complex I by binding the NDUFS2 and NDUFA10 subunits through its DGK domain, with loss of AGK—but not loss of kinase activity—causing mitochondrial dysfunction and hepatic NASH (PMID:35547757), and it binds JAK2 to support thrombopoietin-driven megakaryocyte differentiation and platelet production, a role abolished by AGK deletion but preserved in kinase-dead animals (PMID:32202634). AGK's kinase activity is separately deployed in platelets to phosphorylate Talin-1 at Ser425 and potentiate αIIbβ3 integrin signaling and thrombus formation, without affecting bulk platelet lipid synthesis (PMID:37051931). In disease contexts AGK is co-opted to drive oncogenic signaling: ZDHHC2-mediated S-palmitoylation relocates AGK from mitochondria to the plasma membrane to activate PI3K-AKT-mTOR signaling (PMID:37078777), and in CLL cells aberrant AGK assembles with HSP90 and JAK2 to activate JAK2 in a cytokine-independent manner, directing non-canonical histone H3(Y41) phosphorylation and transcriptional reprogramming (PMID:39636206). Additional functions—local regulation of the mitochondrial ROMK2 channel via LPA production (PMID:38056763)—extend its role at the interface of mitochondrial lipid metabolism and membrane signaling.

1. 2004 High

   Established AGK's fundamental biochemical identity—answering whether it was an enzyme and on what substrates—by defining it as a membrane-associated multi-substrate lipid kinase.

   Evidence Recombinant in vitro kinase assays across multiple lipid substrates with fractionation and pharmacological profiling

   PMID:15252046

   Open questions at the time

   • Did not resolve the physiological in vivo substrate(s)
   • Internal membrane compartment identity not precisely defined
   • No structural basis for substrate selectivity
2. 2020 High

   Revealed that AGK has a kinase-independent function, binding JAK2 to drive megakaryocyte development, separating its enzymatic role from a structural/signaling role.

   Evidence Reciprocal Co-IP plus megakaryocyte/platelet-specific knockout and G126E kinase-dead knock-in mice with platelet phenotyping

   PMID:32202634

   Open questions at the time

   • Structural basis of AGK-JAK2 interaction not defined
   • How JAK2 V617F enhances binding mechanistically unresolved
   • Whether mitochondrial localization is required for JAK2 binding unclear
3. 2022 High

   Demonstrated AGK maintains respiratory chain complex I integrity through direct, kinase-independent binding to NDUFS2 and NDUFA10, explaining its mitochondrial structural role.

   Evidence Reciprocal Co-IP with DGK-domain mapping plus hepatocyte-specific knockout vs kinase-dead knock-in mice in NASH models

   PMID:35547757

   Open questions at the time

   • Stoichiometry and assembly step of AGK within complex I biogenesis not defined
   • No structural model of the AGK-NDUFS2/NDUFA10 interface
   • Tissue-specificity of the complex I requirement unresolved
4. 2023 Medium

   Identified a kinase-dependent substrate of AGK—Talin-1 Ser425—linking its catalytic activity to integrin-mediated platelet activation rather than bulk lipid synthesis.

   Evidence Co-IP and mass spectrometry substrate identification with G126E knock-in mice and in vivo thrombosis models

   PMID:37051931

   Open questions at the time

   • Direct phosphotransfer to Talin-1 not reconstituted in vitro
   • Whether AGK acts as a protein kinase or via a lipid intermediate unclear
   • Single-lab finding
5. 2023 Medium

   Showed that post-translational palmitoylation can reroute AGK out of mitochondria to the plasma membrane to engage PI3K-AKT-mTOR signaling, establishing regulated relocalization as a functional switch.

   Evidence Palmitoylation assays, subcellular fractionation, and pathway analysis in ccRCC cells and xenografts

   PMID:37078777

   Open questions at the time

   • Direct molecular link between membrane AGK and PI3K activation not defined
   • Whether kinase activity is required at the plasma membrane unclear
   • Single-lab finding
6. 2023 Medium

   Connected AGK's lipid product to ion channel regulation, showing localized LPA synthesis modulates the mitochondrial ROMK2 channel.

   Evidence TurboID proximity labeling and Co-IP with artificial bilayer electrophysiology and docking

   PMID:38056763

   Open questions at the time

   • In situ requirement of AGK for ROMK2 activity not shown genetically
   • Physiological consequence of ROMK2 modulation undefined
   • Single-lab finding
7. 2025 Medium

   Defined a pathological non-canonical signaling axis in which AGK-HSP90-JAK2 complexes activate JAK2 to phosphorylate histone H3(Y41) and reprogram transcription, extending AGK's JAK2 partnership into the nucleus.

   Evidence Co-IP, nuclear fractionation, pH3(Y41) Western blots, and JAK2 inhibition/apoptosis assays in primary CLL cells

   PMID:39636206

   Open questions at the time

   • Mechanism of AGK nuclear translocation not established
   • Whether AGK kinase activity contributes is unclear
   • Generality beyond CLL unknown

• It remains unresolved how AGK partitions between its kinase-dependent and kinase-independent functions and how its subcellular localization (mitochondria, plasma membrane, nucleus) is coordinated across cell types.
• No unified structural model linking lipid-kinase and scaffold functions
• Regulators governing AGK relocalization incompletely mapped
• Direct vs indirect nature of several signaling outputs (PI3K, NF-κB, Hippo) not biochemically established